Telix Pharmaceuticals Limited (TLX) Stock Analysis

Telix Pharmaceuticals Limited (TLX) is a publicly traded company in the HEALTHCARE sector. It trades at $9.16, carries a market capitalization of $3.19B. This page summarizes the public market data, fundamentals, and frequently asked questions for TLX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Telix Pharmaceuticals Limited currently has a Bullish sentiment score of 0.33.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is an innovative commercial-stage biopharmaceutical company dedicated to advancing the field of radiopharmaceuticals for the diagnosis and treatment of cancer and rare diseases. With its headquarters in North Melbourne, Australia, Telix operates in key markets including the United States, Belgium, Japan, and Switzerland, leveraging its expertise to deliver cutting-edge therapeutic and diagnostic solutions. The company's strategic focus on unmet medical needs unde...

GNG Research Analysis

GNG Research scores Telix Pharmaceuticals Limited (TLX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TLX.

Frequently Asked Questions

Does TLX pay dividends?

Telix Pharmaceuticals Limited (TLX) does not currently pay a regular dividend.

What is TLX's market cap?

Telix Pharmaceuticals Limited (TLX) has a market capitalization of $3.19B with a current stock price of $9.16.